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Sustained DNA delivery from polymeric ﬁlms provides a means for localized and prolonged gene
therapy. However, in the case of bioactive molecules such as plasmid DNA pDNA, there are
limitations on the achievable release proﬁles as well as on the maintenance of bioactivity over time.
In this report, the authors have investigated the bioactivity of the released DNA naked and
complexed with lipofectamine from polymeric ﬁlms using in vitro cell transfection of COS-7 cell
lines. The polymeric system consists of a biodegradable semicrystalline polymer such as
poly-caprolactone PCL with or without blended gelatin. Sustained release of lipoplexes and of
pDNA is shown over several days. However, lipoplexes released from pure PCL ﬁlms show no
transfection on day 18, whereas lipoplexes released from PCL-gelatin ﬁlms continue to transfect
cells on day 18 of release. Confocal studies were used to determine the reasons for this difference
in transfection efﬁciency, and it is proposed that association of the lipoplex with gelatin confers
protection from degradation in the cytoplasm. The results also showed that the bioactivity of
released lipoplexes was superior to that of the naked pDNA. For both naked pDNA and the
lipoplexes, the presence of gelatin helped to maintain the bioactivity over several days. © 2010
American Vacuum Society. DOI: 10.1116/1.3493692
I. INTRODUCTION
Most of the research in DNA delivery is focused on de-
veloping new carriers that can match the transfection rates
exhibited by viral vectors. However, another aspect of DNA
delivery, that of localizing and sustaining its release, has not
received as much attention. This feature is also critical as it
enhances the availability of the pDNA at the site of action
and sustains its availability over time, so that the frequency
of injections may be reduced.
The advantages of such sustained release polymeric gene
delivery systems may be summarized.1,2
• Sustained delivery of plasmid DNA at the tissue site offers
a source for continual gene uptake, thereby prolonging the
gene expression.
• There are increased amounts of plasmid DNA pDNA up-
take.
• Site speciﬁc delivery can be achieved by simple implanta-
tion or direct injection.
• Repeated administration is not necessary.
Although in recent years sustained release systems have
been successfully employed to deliver proteins and macro-
molecules, successful development of sustained release
pDNA systems has not been reported. Existing studies con-
centrate mainly on microsphere formulations and not on im-
plantable ﬁlms or coatings. Furthermore, detailed investiga-
tions of the bioactivity of the release pDNA have not
received much attention. Sustaining the release of the gene
vector over several days or months, with prolonged and con-
tinuous DNA delivery to tissues, will enhance gene
expression.3
Earlier, we reported the sustained delivery of complexed
and naked pDNA from poly-caprolactone PCL polymer
matrices.4,5 The work was mainly focused on the control of
pDNA and complexed DNA release, as well as on a compari-
son of lipoplex and polyplex release. In brief, the ﬁndings of
that study are summarized as follows.
1. There was a substantial burst release of naked plasmid
DNA from all ﬁlms studied.
2. When lipoplexes are released from PCL, there is no burst,
but release is slow and sustained over 1 month.
3. Addition of gelatin to the PCL matrix increases the re-
lease rate overall of lipoplexes, and sustains it for 1
month.
4. When transfection efﬁciency of the released lipoplexes is
a
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evaluated, it was found that the efﬁciency drops over
time. Without gelatin, lipoplexes released from PCL ﬁlms
do not transfect at all even on day 5. Addition of gelatin
to the matrix allows for sustained bioactivity up to day
19.
This article explores the possible reasons for changes in
transfection efﬁciency by monitoring the bioactivity and in-
tracellular tracking of the lipoplexes released from polymer
ﬁlms.
PCL is a semicrystalline, biocompatible, and biodegrad-
able polyester with a low melting point 57 °C and a low
glass transition temperature. It degrades slowly relative to
the polylactide/polylactide-co-glycolide PLG polymers.
The amorphous portion of PCL is rubbery at room tempera-
ture, and this characteristic contributes to the very high per-
meability of PCL for many therapeutic drugs. PCL exhibits
certain desirable characteristics for drug-delivery applica-
tions, including biodegradability, biocompatibility, and com-
mercial availability.2,6–8 PCL is known to degrade in vitro
and in vivo by a hydrolytic mechanism, although the rate of
degradation is slow. One study reported that degradation of
semicrystalline polyester PCL in aqueous media occurs in
two steps: The ﬁrst step starts with water diffusion into the
amorphous regions, and the second step starts with the hy-
drolytic degradation of the crystalline domains after most of
the amorphous regions degraded.9–12 Other authors reported
that PCL is also degraded by a number of microorganisms
and enzymes such as lipases.9
Gelatin is a natural polymer, derived from collagen, and is
commonly used for pharmaceutical and medical applications
because of its biodegradability and biocompatibility in physi-
ological environments.13–17 In our study, blends of gelatin
with PCL appeared to give the best release proﬁle and bio-
activity retention of the formulations studied.
Other polymer matrices have been explored for the deliv-
ery of plasmid DNA. However, DNA encapsulation efﬁ-
ciency is very low with polylactic-glycolic acid PLGA,
and DNA damage has been observed as result of PLGA deg-
radation and degradation products.18 Howard et al. observed
a sustained release proﬁle of the polyethylenimine/DNA
complex from PLGA microparticles, but a signiﬁcant initial
burst was found.19 Hydrogels have been used to increase
encapsulation efﬁciency, but the release rates are too high to
be of much practical use as a sustained release system for
long periods. For example, Sacks et al. observed a substan-
tial 50% burst effect of the lipofectamine-pDNA complex on
day 1 from collagen ﬁlms.20
Rives et al. fabricated layered porous PLG scaffolds for
the in vivo plasmid DNA delivery. They observed that the
incorporation efﬁciency of plasmid DNA signiﬁcantly in-
creased with layering and that the transgene expression was
sustained over a period of 1–2 weeks with a peak in expres-
sion levels around day 4 or 5, and then there is a decline.21
But a large initial burst effect was observed within the ﬁrst 3
days.21 In our earlier work, we found sustained release of
complexed pDNA as lipoplex over almost a month using
gelatin in a blend with PCL.5 Gelatin extends the duration of
release of bioactive complexed pDNA, but transfection efﬁ-
ciency decreased around day 19. In this report, we explore
the characterization of the released complex pDNA to pro-
vide some insight into the bioactivity preservation with gela-
tin blends and the decline in bioactivity around day 19.
II. EXPERIMENT
A. Materials
The dual vector pEGFPLuc EGFP is enhanced green
ﬂuorescent protein, encoding a fusion protein of EGFP and
luciferase from the ﬁreﬂy Photinus pyralis, was purchased
from Clontech supercoiled, 6.4 kb. It was propagated ac-
cording to the standard method using a giga ﬁlter kit from
Qiagen and was conditioned in an autoclaved TE buffer. Li-
pofectamine LPF was purchased from Invitro Life Tech-
nologies. Sodium oleate salt was purchased from Sigma
Chemicals; it was dissolved in water at a concentration of 1
mg/ml. Ethidium bromide was purchased from Sigma
Chemicals. It was diluted in water at a concentration of
80 g /ml. Polycaprolactone Mn 80 000; polydispersity in-
dex 1.4 and gelatin type A, medium bloom: 175, Mn
40 000 low molecular LMW and type A; high bloom:
300, Mn 50 000–100 000 high molecular weight HMW
were purchased from Sigma Chemicals as well. Chloroform
GR grade was purchased from Tedia. The ﬁlms were cast
with the Automatic Film applicator AG-2150, which was
purchased from BKY Gardner. Dulbecco’s minimum essen-
tial medium DMEM and penicillin-streptomycin were pur-
chased from Invitrogen. A Luciferase Reporter Assay Kit
was purchased from BD Clontech. A Micro BCATM Protein
Assay Reagent Kit was purchased from Pierce Biotechnol-
ogy, Rockford, IL. Oregon Green® 488 gelatin was pur-
chased from Molecular Probes. 4,6-diamidino-2-
phenylindole DAPI, ex=345 nm, em=460 nm was pur-
chased from Invitrogen. Propidium iodide PI, ex=546 nm,
em=575–640 nm was purchased from Aldrich.
B. Preparation of lipofectamine-pDNA complexes
pDNA was diluted to a working range of 28 g in
100 l 280 g /ml. Lipofectamine was diluted using a
serum-free medium SFM: DMEM without the addition of
fetal bovine serum FBS. Different LPF/DNA w/w ratios
were used to optimize the lipoplexes for the ﬁlm loading
part, and a LPF/DNA ratio of 8 w/w was selected as a
standard for the complex preparation for the ﬁlm loading part
as higher transfection efﬁciency was observed at this w/w
ratio data not shown here. Lipofectamine was added to the
pDNA such that the lipofectamine was eight times the weight
of pDNA. The complexes were vortexed vigorously, and
then they were incubated at room temperature for 30 min. No
agglomeration was noted in the sample preparation.
C. Preparation of gelatin solution
Gelatin solution 10% w/v was prepared in water w/v
and autoclaved.
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D. Incorporation of complex into the PCL ﬁlms
A 6.6% w/v PCL solution was made by dissolving the
polymer in chloroform. Then, 300 l of PCL solution was
mixed with 100 l of SFM containing LPF/DNA or pDNA,
and the mixture was vortexed at 2200 rpm and was cast as a
ﬁlm. Gelatin-containing ﬁlms were prepared by adding a
gelatin solution to obtain a gelatin content of 10% w/w in
the ﬁnal ﬁlm to SFM containing LPF/DNA or pDNA.
All ﬁlms were dried in the laminar hood for 3 days to
enable the evaporation of the solvent. The speciﬁc concen-
trations selected here are based solely on the quality of the
emulsion obtained. The choice of chloroform is mandated by
pDNA activity retention in chloroform compared to other
organic solvents. To determine this effect of solvent on bio-
activity, we incubated the lipoplex with 300 l of different
solvents acetone, chloroform for 1 h and then carried out
the transfection studies. Lipoplexes prepared with fresh
SFMs were used as a control.
E. Fluorescence imaging of pDNA, lipoplex, and
gelatin onto polymer ﬁlms
The spatial distribution of pDNA, lipoplexes, and gelatin
in the polymer ﬁlms was determined by a confocal ﬂuores-
cence microscope Leica TCS SP5 equipped with a UV la-
ser 405 nm to induce the blue ﬂuorescence of DAPI with
345 nm excitation wavelength and emission wavelength at
460 nm. Green ﬂuorescence of Oregon Green 488-tagged
gelatin was induced by the 488 nm laser 488 nm excitation
and detected at 515–565 nm wavelengths. The images were
taken by a sequential scan and were later processed and ana-
lyzed by LAS AF software. Polymeric ﬁlms with and without
ﬂuorescent labeled gelatin Oregon Green® 488 Gelatin
were prepared as described above by the emulsion technique
for the incorporation of pDNA and lipoplexes. However,
prior to the formation of lipoplexes, DNA was labeled with
blue-ﬂuorescent dye, DAPI. For confocal imaging, dry poly-
mer ﬁlms were washed with phosphate buffered saline PBS
and then imaged immediately on a Leica confocal ﬂuores-
cence microscope.
F. Bioactivity studies
The pDNA and lipoplex were released from the polymer
ﬁlms, and the released amounts were quantiﬁed using
ethidium bromide EtBr, as described in our previous
report.5 The released pDNA/lipoplexes were collected at pre-
determined intervals, and a volume containing 0.5 g of
DNA pDNA/lipoplex was then used for transfection stud-
ies.
Samples were air dried in the laminar hood for a few
hours and resuspended in SFM 0.5 ml. COS-7 cells were
seeded in 24-well tissue culture grade plates at 2
104 cells per well and were grown overnight to approxi-
mately 80% conﬂuence under normal growth conditions. On
the following day, the cell culture medium was removed, and
SFM containing the released pDNA/lipoplexes was added to
the cells. The cells were incubated with pDNA/complexes at
37 °C in a 5% CO2 incubator for 5 h. The medium was
replaced with 0.5 ml of 2X medium and was left overnight;
0.5 ml of 1X medium was added on the following day. Lu-
ciferase activity was determined using a Luciferase assay kit
BD Sciences after 48 h of transfection. The total protein
was assayed using a Micro BCA protein assay Pierce, Rock-
ford, IL. The activity was normalized to the total protein
content.
G. Particle size measurement
Particle size measurement of the LPF/pDNA complexes
was performed by photon correlation spectroscopy PCS us-
ing Zeta Sizer NS Malvern Instruments Ltd., Malvern,
U.K.. Samples were diluted in PBS and measured in glass
cuvettes at 25 °C and a scattering angle of 90°.
H. Cellular tracking of pDNA/lipoplexes by confocal
ﬂuorescence microscopy
COS-7 cells 1105 cells /well were cultured in a six-
well culture dish for 24 h in 1 ml of the DMEM medium
supplemented with 10% FBS 10% FBS DMEM and were
grown overnight to approximately 80% under normal growth
conditions under a humidiﬁed atmosphere of 5% CO2 in air.
On the following day, the medium was removed and the air
dried released samples were treated with fresh SFM 0.5 ml.
This was added to the cells. The cellular entry of PI labeled
pDNA/complexes was monitored by a confocal ﬂuorescence
microscope Leica TCS SP5. First, the cells treated with
samples were ﬁxed with 4% paraformaldehyde in PBS for 30
min at room temperature. After washing twice with PBS, the
coverslips were mounted on glass microscope slides by using
a drop of antifade solution, diazabicyclooctan 2.5% w/v.
Then, the samples were observed under confocal laser scan-
ning microscopy with an argon laser 488 nm excitation to
induce the green ﬂuorescence of Oregon green, and their
emission was observed using a band ﬁlter 515–565 nm.
Red ﬂuorescence was induced by the 546 nm excitation and
detected at 575–640 nm wavelengths. However, prior to
loading the lipoplexes into the polymer ﬁlms, plasmid DNA
was labeled with PI ex=546 nm, em=575–640 nm. PI
a red dye is more contrasting against gelatin labeled green
inside the cell. So, it was used to label the lipoplex/pDNA. In
this case, DAPI was used to stain the nucleus of the cell so as
to differentiate between the nucleus and the lipoplex/pDNA
entering the cell. Plasmid DNA was mixed with PI at a 1:1
weight ratio of pDNA to PI in the TE buffer 10 mM tris-
HCl; 1 mM ethylenediamine tetra-acetic acid; pH 7.4. The
solution was incubated for 1 h at room temperature in the
dark, and the mixture was dialyzed to remove the free PI.
I. Statistical analysis
All the experiments were performed in triplicates, and all
the data were presented as mean  standard deviations.
Analysis of variance has been done to indicate the statistical
signiﬁcance of the observations. Differences were considered
statistically signiﬁcant at p0.05.
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III. RESULTS AND DISCUSSION
A. Fluorescence imaging studies of PCL/gelatin ﬁlm
When a bioactive molecule is incorporated in a polymer
ﬁlm, it may be either dispersed or dissolved in the matrix.
Both pDNA and lipoplex, when incorporated in PCL, are
expected to be dispersed in the hydrophobic PCL matrix as
both of them are considered fairly hydrophilic relative to
PCL. However, because of the partial hydrophobicity due to
the fatty acid chain, lipoplexes dissolve more in the hydro-
phobic PCL matrix compared to pDNA. When gelatin is
blended with PCL, the distribution of pDNA or the lipoplex
may be substantially different. First, to characterize the dis-
tribution of pDNA, lipoplexes, and gelatin in the PCL ﬁlm,
ﬂuorescence imaging studies were performed by confocal
ﬂuorescence microscopy. Plasmid DNA was labeled with
DAPI, a blue-ﬂuorescent nucleic acid stain, which preferen-
tially stains dsDNA, and lipoplex was prepared with DAPI
labeled pDNA.
Figures 1a and 1b show the pDNA and lipoplex distri-
bution in a PCL ﬁlm with ﬂuorescent labeled gelatin Oregon
Green® 488 Gelatin. We could see some regions of overlap
between pDNA/lipoplex and gelatin phases, indicating some
degree of miscibility between pDNA/lipoplex and gelatin.
So, it is clear that both pDNA and lipoplex tend to associate
with gelatin rather than with the continuous matrix PCL. In
other words, immiscibility in the PCL regions of the ﬁlms
indicates the preferential partitioning of pDNA and lipoplex
in gelatin as compared to PCL.
B. Bioactivity studies
Transfection experiment was carried out to evaluate the
bioactivity of complexed DNA lipoplex using different sol-
vents. Figure 2 shows the effect of solvents on the bioactivity
of lipoplexes. Transfection efﬁciency was much better with
chloroform when compared with the other solvent acetone.
Since the chloroform seems to affect the complexed DNA
lipoplex much less than acetone, it was decided to use chlo-
roform as a solvent for the ﬁlm’s formulations.
The bioactivity of the released DNAwas determined by in
vitro cell transfection efﬁciency using COS-7 cell lines.
Transfection efﬁciency of released DNA pDNA/complexed
DNA from polymer ﬁlms was observed by an inverted
phase contrast microscope. The transfection is quantiﬁed by
using enzyme luciferase activity, normalized using the total
protein content of cell extracts. Transfection efﬁciency of
released DNA from polymer ﬁlms was studied at all the time
points for the release study.
Figure 3 shows the comparative transfection efﬁciency of
pDNA and lipoplex released from PCL ﬁlms with gelatin on
day 5. Transfection efﬁciency of the released pDNA is much
lower than lipoplexes as expected. This is mainly due to the
repulsion of the negatively charged DNA 78 mV and the
negatively charged cell membrane and to the consequent
lesser ability to penetrate the cell membrane, whereas the
complex carries a net positive charge. In addition, the lower
mobility of pDNA in the cytoplasm may also contribute to a
lower observed transfection efﬁciency assessed after 24 h of
incubation. Thus, lower transfection efﬁciency is mainly due
to the large size and the negative charge density of
pDNA.22,23
Figure 4 shows the comparison of transfection efﬁciency
of released lipoplexes from PCL ﬁlms with lipoplexes free
incubated in PBS. Clearly, incubating lipoplexes in a buffer
over 20 days does not alter the transfection efﬁciency,
FIG. 1. Color online Confocal images of a PCL ﬁlm with labeled pDNA
and labeled gelatin and b PCL ﬁlm with lipoplex prepared with labeled
DNA and labeled gelatin.
FIG. 2. Color online Effect of solvents on bioactivity of lipoplex.
FIG. 3. Color online Transfection of released pDNA vs lipoplexes from
PCL/gelatin ﬁlms.
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whereas lipoplexes released from polymer ﬁlms show a drop
over time. In particular, lipoplexes released from PCL ﬁlms
show no transfection at all, even on day 5. Second the addi-
tion of either low-MW or high-MW gelatin substantially in-
creases the transfection efﬁciency compared to lipoplexes re-
leased from PCL ﬁlms Table I. We discuss the reasons for
this further below based on the details of intracellular traf-
ﬁcking. When we compare the high- and low-MW gelatin, it
appears that by day 18, only the ﬁlm with high-MW gelatin
continues to release a bioactive lipoplex. In general, how-
ever, the transfection efﬁciency decreases over time of resi-
dence in all the polymer ﬁlms.
Various possibilities can be postulated for such decreased
transfection efﬁciency, e.g., reduced DNA release, reduced
pDNA transfection capability, and degradation of DNA. In
our previously reported work,4,5 we found that there is an
adequate amount of lipoplexes released from the matrices
under study. So, we can rule out the possibility of reduced
release from the matrix. As far as transfection capabilities are
concerned, we have observed reasonable transfection in the
early release time points, which shows that lipoplexes have
retained their transfection capability. The third possibility,
lysosomal degradation of the lipoplex, seems to be the more
likely explanation as there is reduction in transfection efﬁ-
ciency with time. What causes this increased degradation in
the cytoplasm is not clear to us at present
In order to further explore the reasons for the differences
in the transfection efﬁciencies of the released lipoplexes, the
extent of decomplexation of the lipoplex Table II, as well
as the particle size of the released lipoplexes, was deter-
mined. From the particle size data Table III, it is clear that
one of the reasons for decreased transfection with the time of
release is aggregation of the released complexes compared
to the lipoplex in the buffer, which reduces nuclear penetra-
tion. The size of the released lipoplexes from PCL ﬁlm in-
creases to 590 nm, while those released from PCL/LMW
gelatin ﬁlms increases to about 700 nm and to about 710 nm
from PCL/HMW gelatin ﬁlms by day 18. In contrast, li-
poplexes incubated in a buffer for the same length of time
show an increase in size from about 60 nm on day 0 to about
175 nm on day 18 Table III. Although there is a possibility
of detecting gelatin molecules, which could be present in the
sample, the size distribution was obtained in a single peak,
and thus we can conﬁrm that the lipoplexes fall in the same
size range.
So, one of the factors for reduced transfection of the re-
leased lipoplexes is increased size. However, this factor does
not explain why the released lipoplexes from PCL/gelatin
ﬁlms continue to show some transfection while those re-
leased from PCL ﬁlms which are actually smaller in size do
not transfect at all. This difference must be related to the
intracellular fate of these particles or to the decomplexation
of the lipoplexes.
Considering the degree of decomplexation, however, we
ﬁnd that Table II released lipoplexes from PCL in fact
show complete retention of the complexed form. Thus, nei-
ther aggregation nor decomplexation levels explain why
FIG. 4. Color online Comparison of transfection of released lipoplexes
from ﬁlms with lipoplexes incubated in PBS.
TABLE I. Amount of transfection fg/mg of protein of released DNA from
different polymer ﬁlms.
Samples
Transfection amount fg/mg of protein
Lipoplex pDNA
Day 5 Day 9 Day 18 Day 5
PCL ¯ ¯ ¯ ¯
PCL/LMW gelatin 1.0010+06 8.3510+05 ¯ 1.5010+04
PCL/HMW gelatin 9.7510+05 7.3210+05 1.1310+05 1.0710+04





Day 5 Day 9 Day 18
PCL/lipoplex 100 100 100
PCL/LMW gelatin/lipoplex 79 85 90
PCL/HMW gelatin/lipoplex 72 80 86
TABLE III. Particle size of lipoplexes lipoplexes incubated in PBS vs re-




Day 0 Day 5 Day 9 Day 18
Lipoplex incubated in PBS 606 1209 1605 1808
PCL/lipoplex ¯ 44011 5309 59013
PCL/LMW gelatin/lipoplex ¯ 46012 5158 7006
PCL/HMW gelatin/lipoplex ¯ 4209 5307 71010
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gelatin-containing ﬁlms release more bioactive lipoplexes.
For this, we need to examine the details of the intracellular
trafﬁcking of these lipoplexes.
C. Cellular tracking of pDNA/lipoplexes by confocal
ﬂuorescence microscopy
In order to determine the reasons for the different levels
of transfection observed from different ﬁlm types, a study
was undertaken to determine the intracellular localization of
pDNA and lipoplexes at different time points. The cell
nucleus was labeled with DAPI staining blue color. Confo-
cal laser spectroscopy was used to track the lipoplex and/or
naked pDNA.
Figures 5 and 6 show the intracellular distribution of day
5 released lipoplexes and gelatin, taken 2 and 24 h after
transfection, respectively. Figure 5 clearly shows the red
ﬂuorescence PI labeled pDNA within the lipoplex in the
cell cytoplasm Fig. 5b as well as the green ﬂuorescence
of gelatin in the cell cytoplasm Fig. 5c. Thus, lipoplexes
and gelatin are both internalized in an associated manner
through the cell membrane, and after 2 h of incubation with
COS-7 cells, lipoplexes and gelatin are present at or near the
region of the cell nucleus. The merged image Fig. 5d
shows the colocalization of lipoplex and gelatin in the cyto-
plasm. It is noteworthy that inside the cytoplasm, the gelatin
is always associated closely with the lipoplex, with few un-
associated complexes to be found elsewhere. The possibility
of “cross-talk” between the gelatin and lipoplex ﬂuorescence
has been eliminated by sequential scanning at different laser
wavelengths.
Figure 6 shows the cellular distribution of particles 24 h
after transfection. We now see red and green ﬂuorescences
within the cell nucleus a white arrow indicates the presence
of red ﬂuorescence, indicating that these gelatin-associated
particles can still enter the nucleus. In vitro size measure-
ment of the released lipoplexes on day 5 shows particles of
around 460 nm. Since the nuclear pores allow free diffusion
entry only for small particles 	50 nm, this unexpected
entry of the larger particles 460 nm into the nucleus may
occur either because the particles inside the cytoplasm are in
fact much smaller than 460 nm or because such particles
may have entered during the cell division when the nuclear
membrane temporarily breaks down.24,25 We cannot also rule
out disassociation of the lipoplex prior to nuclear entry.
In contrast, let us examine the fate of lipoplexes released
from PCL ﬁlms no gelatin. For lipoplexes released from a
PCL matrix, Figs. 7 and 8 show the red ﬂuorescence PI
FIG. 5. Color online Intracellular distributions of released lipoplexes and
gelatin at day 5 from PCL/gelatin ﬁlm 2 h after transfection. a Blue
ﬂuorescence indicates the nucleus. b Red ﬂuorescence indicates the local-
ization of lipoplexes. c Green ﬂuorescence indicates the localization of
gelatin. d Merged image of all ﬂuorescence.
FIG. 6. Color online Intracellular distributions of released lipoplexes and
gelatin at day 5 from PCL/gelatin ﬁlm 24 h after transfection. a Blue
ﬂuorescence indicates the nucleus. b Red ﬂuorescence indicates the local-
ization of lipoplexes white arrow indicates the presence of red ﬂuorescence
in the nucleus. c Green ﬂuorescence indicates the localization of gelatin.
d Merged image of all ﬂuorescence.
FIG. 7. Color online Intracellular distributions of released lipoplexes from
PCL at day 5 2 h after transfection. a Blue ﬂuorescence indicates the
nucleus. b Red ﬂuorescence indicates the localization of lipoplexes. c
Merged image of all ﬂuorescence.
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labeled DNA in the cell cytoplasm and near the nuclear
membrane, but the ﬂuorescence does not reach into the
nucleus, even 24 h after transfection.
Figure 9 makes a side-by-side comparison of lipoplexes
released from PCL and from PCL/gelatin ﬁlms on day 5.
Figure 9a shows that some of the lipoplexes released from
PCL/gelatin ﬁlms do in fact enter the nucleus, whereas this is
not the case for the lipoplexes released from PCL Fig. 9b.
It should also be noted that on a relative basis, there are
many more lipoplexes with gelatin inside the cytoplasm
compared to lipoplexes from PCL ﬁlms.
Similar observations have been made for day 9 and day
18 data not shown. From the intracellular trafﬁcking pic-
tures, it appears that gelatin-associated lipoplexes enter the
cytoplasm in larger numbers and some of them penetrate the
nucleus to show transfection. In contrast, fewer of the li-
poplexes released from PCL without any gelatin associa-
tion appear to be in the cytoplasm after 24 h of incubation,
and none appear to penetrate the nucleus.
Thus gelatin-associated lipoplexes appear to survive in
the cytoplasm long enough to allow for some to enter the
nucleus. This protection afforded by gelatin has been previ-
ously observed in gelatin particles with incorporated plasmid
DNA.26 In that study, smaller gelatin nanoparticles entered
the cells by nonspeciﬁc endocytosis and then survived endo-
somal attack in the cytoplasm, as observed by the visualiza-
tion of the tagged particles in confocal microscopy. The rea-
son for this protection is not entirely clear, although it is
likely that the endosomal pH of 5–5.5 is not low enough to
degrade gelatin the measured pH of our gelatin solutions is
around 4.7, and the lipoplexes are most likely coated with a
layer of gelatin.
There is a size effect on transfection efﬁciency. In general,
lower sizes allow for greater transfection. In order to illus-
trate what happens with lipoplexes simply incubated in a
buffer, we show the images in Fig. 10. Such incubated li-
poplexes grow in size upon incubation, but only to about 170
nm after 18 days. It is clear that much larger numbers of
lipoplexes are present in the case of the incubated lipoplexes
compared to the released lipoplexes inside the cytoplasm,
and more also enter the nucleus Figs. 10b and 10d. This
difference in behavior is due substantially to a size effect, as
explained above, as the lipoplexes incubated in a buffer do
not increase in size over 18 days as much as the released
lipoplexes do Table III. However, sizes are roughly compa-
rable for lipoplexes released from PCL and from PCL/
gelatin, so size is not the reason for the observed differences
in the bioactivity of the released lipoplexes from these ﬁlms.
Clearly, there is protection conferred by the associated gela-
tin.
The possibility of autoﬂuorescence of lipofuscin oxida-
tive stress product within lysosomes was ruled out as the
confocal images of the control cells treated with lipo-
fectamine same amount as lipoplex did not show any ﬂuo-
rescence data not shown here. The reason could be the
FIG. 8. Color online Intracellular distributions of released lipoplexes from
PCL at day 5 24 h after transfection. a Blue ﬂuorescence indicates the
nucleus. b Red ﬂuorescence indicates the localization of lipoplexes. c
Merged image of all ﬂuorescence.
FIG. 9. Color online Comparison of intracellular distributions of released
lipoplexes at day 5 from a PCL/gelatin ﬁlm white arrow indicates the
presence of red ﬂuorescence in the nucleus, b PCL ﬁlm 24 h after
transfection.
FIG. 10. Color online Comparison of intracellular distributions of released
lipoplexes with lipoplexes incubated in buffer. a Released lipoplexes PCL/
gelatin ﬁlm at day 5. b Lipoplexes incubated in buffer at day 5. c Re-
leased lipoplexes PCL/gelatin ﬁlm at day 9. d Lipoplexes incubated in
buffer at day 9 24 h after transfection.
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amount of lipofuscin oxidative stress product within lysos-
omes is not enough to produce the autoﬂuorescence.
To summarize, we observed the following.
i Released lipoplexes from PCL ﬁlms do not show any
transfection on days 5, 9, and 18. These lipoplexes are
larger in size compared to lipoplexes incubated for
similar lengths of time in buffer and are also fully
complexed Table II. However, confocal studies
show very few lipoplexes inside the cytoplasm and
none at all in the nucleus. We believe that this is most
likely due to endosomal/lysosomal degradation of the
larger particles.
ii When lipoplexes are released from PCL-gelatin ﬁlms,
they could be associated with gelatin. In the cyto-
plasm, this association is clearly seen using confocal
microscopy. Such lipoplexes appear to be in the cyto-
plasm in larger numbers, with some of them reaching
the nucleus in spite of their large size. Thus, gelatin
association of the lipoplex appears to protect them
from endosomal/lysosomal degradation. At this point,
we are not sure of the mechanism for this protection,
and further studies are planned to address this.
iii In general, larger-sized lipoplexes ﬁnd it more difﬁ-
cult to penetrate the nucleus. This inference is drawn
from comparing the higher transfection of incubated
lipoplexes which increase modestly in size to about
170 nm with that of the released lipoplexes which
increase in size to about 700 nm.
iv Although it is possible that the increased size may
decrease nuclear penetration, the size effect does not
explain why gelatin-associated particles appear to
transfect even on day 18 while PCL-released li-
poplexes do not they are similar in size and hence
must be able to enter the cell in roughly equal mea-
sure. It is the cytoplasmic fate of these lipoplexes
that appears to be different, as explained above.
It should be mentioned here that we have chosen to use
serum-free media for release and for transfection studies. It is
acknowledged that the presence of serum proteins would in-
ﬂuence the transfection efﬁciency through protein binding to
pDNA,27–29 although other authors have not reported any
effect on the lipoplex uptake.29 Nevertheless, to isolate the
effect of the carrier ﬁlm on the bioactivity of released pDNA
or lipoplex, it is more illustrative to assess this in serum-free
media as the serum proteins may confound the assessment of
bioactivity. This was the main focus of this work.
The site of injection may also play a role: For example,
release in subcutaneous tissue may not involve much inter-
action with serum proteins. So, to understand the differences
in bioactivity induced by the encapsulating polymer, serum-
free media are a good starting point. Future studies will ad-
dress the effects of serum.
IV. CONCLUSIONS
Our group has reported earlier that both naked pDNA
and complexed DNA with cationic agents lipofectamine
can be successfully incorporated into slowly degrading poly-
mer PCL ﬁlms and can be released from these ﬁlms in a
sustained manner. However, the lipoplexes released from dif-
ferent ﬁlms show differing levels of bioactivity, as assessed
by transfection efﬁciency in COS-7 cells. In this study, we
present possible reasons for the observed differences in
transfection levels. Based on the confocal studies, we show
that lipoplexes released from PCL ﬁlms are able to enter the
cells but unable to transfect due to degradation in the
endosomes/lysosomes. On the contrary, association of these
lipoplexes with gelatin enables them to survive this degrada-
tion enough to show transfection up to day 18. However,
increased size of lipoplexes in general leads to reduced trans-
fection due to reduced nuclear penetration. Further studies
are underway to pinpoint the reasons for the protective effect
conferred by gelatin association.
It should be noted that the in vivo situation is likely to be
favorable than the in vitro environment, as released pDNA or
the lipoplex may in fact transfect cells soon after release and
may be less aggregated than in the in vitro case. On the other
hand, serum proteins may play a signiﬁcant role if the pDNA
or lipoplex is meant to exert its action by circulation in
blood.
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